NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free PRFX Stock Alerts $0.86 -0.03 (-3.38%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.83▼$0.8750-Day Range$0.81▼$2.3152-Week Range$0.69▼$26.41Volume23,121 shsAverage Volume405,834 shsMarket Capitalization$1.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PainReform alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About PainReform Stock (NASDAQ:PRFX)PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Read More PRFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRFX Stock News HeadlinesApril 18, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comPainReform Announces Pricing of $4 Million Public OfferingApril 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 9, 2024 | msn.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 4, 2024 | finance.yahoo.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 2, 2024 | finance.yahoo.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | globenewswire.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyMarch 7, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 1, 2024 | globenewswire.comPainReform Provides Year-End Business UpdateJanuary 22, 2024 | finance.yahoo.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 12, 2024 | msn.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 5, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 3, 2024 | finance.yahoo.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefDecember 26, 2023 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 19, 2023 | benzinga.comPainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and DatesNovember 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 15, 2023 | finance.yahoo.comPainReform Provides Business Update for the Third Quarter of 2023November 12, 2023 | morningstar.comPainReform Ltd Ordinary Shares PRFXSeptember 12, 2023 | markets.businessinsider.comPainReform (PRFX) Gets a Buy from Maxim GroupSeptember 11, 2023 | finance.yahoo.comPainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySee More Headlines Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRFX CUSIPN/A CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.65 per share Price / Book0.18Miscellaneous Outstanding Shares2,030,000Free Float1,329,000Market Cap$1.74 million OptionableNot Optionable Beta0.53 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Ehud Geller Ph.D.Executive ChairmanMr. Ilan Hadar M.B.A. (Age 55)CEO & CFO Comp: $404kDr. Sigal Aviel (Age 60)Chief Operating Officer Comp: $345kProf. Eli Hazum Ph.D.CTO & DirectorMs. Rita Keynan (Age 55)Vice President of Pharmaceutical Operations Comp: $302kDr. Stephen A. Cooper D.M.D Ph.D.Executive Vice President of DevelopmentMore ExecutivesKey CompetitorsGalmed PharmaceuticalsNASDAQ:GLMDBio-PathNASDAQ:BPTHLucy Scientific DiscoveryNASDAQ:LSDIInMed PharmaceuticalsNASDAQ:INMQualigen TherapeuticsNASDAQ:QLGNView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 170,000 shares on 2/13/2024Ownership: 10.897%View All Institutional Transactions PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed in 2024? PainReform's stock was trading at $2.75 at the beginning of the year. Since then, PRFX stock has decreased by 68.8% and is now trading at $0.8570. View the best growth stocks for 2024 here. When is PainReform's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PRFX earnings forecast. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) announced its earnings results on Monday, November, 15th. The company reported ($1.80) EPS for the quarter, beating analysts' consensus estimates of ($4.30) by $2.50. When did PainReform's stock split? Shares of PainReform reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU). When did PainReform IPO? PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRFX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
